Clinical trials: Impairment, Cognitive
Cognitive Dysfunction, Cognitive Impairment
CAMCI: Advancing the Use of Computerized Screening in Healthcare
Cognitive impairment is a significant health problem in the United States, resulting in costs over $100 billion a year. We will provide an efficient, effective, and financially intelligent solution to Primary Care Physician's to…
- Conditions
- Cognitive Dysfunction, Cognitive Impairment, Cognitive Decline, Cognitive Change
- Trial name
- NCT03512301
- Testing
- CAMCI, MoCA, Clinical Adjudication
- Where
- 4 sites in United States
- Volunteers
- 773 people, healthy volunteers welcome
- Sponsor
- Psychology Software Tools, Inc.
Schizophrenia, Impaired Cognition
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
- Trial name
- NCT01716975
- Testing
- EVP-6124
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 767 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer Disease, Cognitive Impairment
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study. Participants who complete the Hope Study (CA-0011) will be eligible to consent for screening to enroll…
- Conditions
- Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia, Mild
- Trial name
- NCT06245031
- Testing
- Sensory Stimulation System (GS120) - Active
- Where
- 53 sites in United States
- Volunteers
- 402 people
- Sponsor
- Cognito Therapeutics, Inc.
Cognitive Impairment, Mild
Telerehabilitation Cognitive Impairments Following Chemotherapy Feasibility Study
Develop a game-based upper-extremity motor and cognitive rehabilitation system using custom and adaptable virtual reality simulations on a wearable device enhanced with biosensors.
- Trial name
- TCIFCF (NCT04972019)
- Testing
- Telerehabilitation Experimental Group
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Bright Cloud International Corp
Traumatic Brain Injury
Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment
This study is designed to investigate the efficacy and safety of rivastigmine compared with placebo in patients with traumatic brain injury and cognitive impairment.
- Trial name
- NCT00171795
- Testing
- Rivastigmine
- Volunteers
- 67 people
- Sponsor
- Novartis
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236431
- Testing
- Galantamine hydrobromide
- Volunteers
- 1,063 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease, Cognitive Dysfunction
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive and neuropsychiatric symptoms in participants with mild cognitive impairment (MCI) or mild dementia due to…
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Dementia
- Trial name
- NCT04602624
- Testing
- SAGE-718
- Where
- 10 sites in United States
- Volunteers
- 26 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Alzheimer Disease
A Study of LY3002813 in Participants With Alzheimer's Disease
The study will evaluate the safety of LY3002813 by looking at adverse events. The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT01837641
- Testing
- LY3002813-IV, LY3002813-SC
- Where
- 6 sites in United States, Japan
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Safety and Tolerability of AQW051 in Elderly Healthy Volunteers.
The purpose of this study is to assess safety and tolerability of AQW051 administered in single and multiple doses to elderly healthy volunteers.
- Trial name
- NCT00418002
- Testing
- AQW051
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Novartis
Alzheimer Disease
Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill
This is an estimation-focused Phase 2 study designed to explore and quantify treatment-related changes across multiple clinical outcomes in patients with Alzheimer's disease over a 210-day period.
- Trial name
- NCT06597058
- Testing
- MAR
- Where
- 16 sites in United States
- Volunteers
- 121 people
- Sponsor
- Noah Pharmaceuticals, Inc.
Hunter Syndrome
Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094
This extension study will allow participants that completed Study HGT-HIT-094 to continue receiving Elaprase treatment in conjunction with idursulfase IT or to continue receiving Elaprase treatment and begin concurrent IT…
- Trial name
- NCT02412787
- Testing
- Idursulfase-IT, Elaprase
- Where
- 9 sites in United States, Australia and 5 more
- Volunteers
- 56 people
- Sponsor
- Shire
Alzheimer's Disease
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the potential benefits of CERE-110 in the treatment of Alzheimer's disease. CERE-110 is an experimental drug that is designed to help nerve cells in the brain function better.
- Trial name
- NCT00876863
- Testing
- CERE-110: Adeno-Associated Virus injection Surgery
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Sangamo Therapeutics
Cognitive Impairment, Memory Complaint
Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center
The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients…
- Conditions
- Cognitive Impairment, Memory Complaint, Clinical Investigation in Memory Centers
- Trial name
- DIALOG (NCT02221661)
- Volunteers
- 606 people
- Sponsor
- Diaxonhit
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 2 (NCT06976203)
- Testing
- KarXT, KarX-EC
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Postoperative Complications, Delirium
Donepezil in the Prevention of Post-Operative Cognitive Decline
The purpose of this study is to evaluate the feasibility of using Donepezil to prevent post-operative cognitive decline (POCD) among individuals aged 65 and older who have a baseline mild cognitive impairment (MCI) and are…
- Trial name
- NCT00182845
- Testing
- Donepezil
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pfizer
Alzheimer Disease
Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD
The purpose of this study is to study the effect of monthly dosing with a single dose of Lu AF20513, with and without booster vaccine, on antibody response.
- Trial name
- NCT03819699
- Testing
- Lu AF20513, booster vaccine
- Where
- 3 sites in Finland, Sweden
- Volunteers
- 3 people
- Sponsor
- H. Lundbeck A/S
Mild Cognitive Impairment
Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery
The primary objective is to compare mild cognitive impairment in the AL-208 group with the placebo group at 14 + - 3 days after CABG surgery
- Trial name
- NCT00404014
- Testing
- AL-208
- Where
- 28 sites in United States, Canada
- Volunteers
- 234 people
- Sponsor
- Allon Therapeutics
Cognitive Impairment Associated With Schizophrenia
Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia
To establish the proof of concept that MEM 3454, used as add-on pharmacotherapy, is a safe and effective treatment in patients with cognitive impairment associated with schizophrenia (CIAS).
- Trial name
- NCT00604760
- Testing
- MEM 3454
- Where
- 44 sites in United States
- Volunteers
- 160 people
- Sponsor
- Memory Pharmaceuticals
Hunter Syndrome
Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment
Study HGT-HIT-094 is a multicenter study designed to determine the effect on clinical parameters of neurodevelopmental status of monthly IT administration of idursulfase-IT 10 mg for 12 months in pediatric patients with Hunter…
- Trial name
- AIM-IT (NCT02055118)
- Testing
- idursulfase-IT, No IT treatment
- Where
- 9 sites in United States, Australia and 5 more
- Volunteers
- 58 people
- Sponsor
- Shire
Alzheimer's Disease
Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers
The purpose of this study is to demonstrate that donepezil slows the progression of Alzheimer's disease (AD) using magnetic resonance imaging (MRI) of the brain to measure the volume of the hippocampus in patients with…
- Trial name
- NCT00403520
- Testing
- Experimental 1
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Eisai Inc.